- Sassi, Atfa;
- Lazaroski, Sandra;
- Wu, Gang;
- Haslam, Stuart M;
- Fliegauf, Manfred;
- Mellouli, Fethi;
- Patiroglu, Turkan;
- Unal, Ekrem;
- Ozdemir, Mehmet Akif;
- Jouhadi, Zineb;
- Khadir, Khadija;
- Ben-Khemis, Leila;
- Ben-Ali, Meriem;
- Ben-Mustapha, Imen;
- Borchani, Lamia;
- Pfeifer, Dietmar;
- Jakob, Thilo;
- Khemiri, Monia;
- Asplund, A Charlotta;
- Gustafsson, Manuela O;
- Lundin, Karin E;
- Falk-Sörqvist, Elin;
- Moens, Lotte N;
- Gungor, Hatice Eke;
- Engelhardt, Karin R;
- Dziadzio, Magdalena;
- Stauss, Hans;
- Fleckenstein, Bernhard;
- Meier, Rebecca;
- Prayitno, Khairunnadiya;
- Maul-Pavicic, Andrea;
- Schaffer, Sandra;
- Rakhmanov, Mirzokhid;
- Henneke, Philipp;
- Kraus, Helene;
- Eibel, Hermann;
- Kölsch, Uwe;
- Nadifi, Sellama;
- Nilsson, Mats;
- Bejaoui, Mohamed;
- Schäffer, Alejandro A;
- Smith, CI Edvard;
- Dell, Anne;
- Barbouche, Mohamed-Ridha;
- Grimbacher, Bodo
Background
Recurrent bacterial and fungal infections, eczema, and increased serum IgE levels characterize patients with the hyper-IgE syndrome (HIES). Known genetic causes for HIES are mutations in signal transducer and activator of transcription 3 (STAT3) and dedicator of cytokinesis 8 (DOCK8), which are involved in signal transduction pathways. However, glycosylation defects have not been described in patients with HIES. One crucial enzyme in the glycosylation pathway is phosphoglucomutase 3 (PGM3), which catalyzes a key step in the synthesis of uridine diphosphate N-acetylglucosamine, which is required for the biosynthesis of N-glycans.Objective
We sought to elucidate the genetic cause in patients with HIES who do not carry mutations in STAT3 or DOCK8.Methods
After establishing a linkage interval by means of SNPchip genotyping and homozygosity mapping in 2 families with HIES from Tunisia, mutational analysis was performed with selector-based, high-throughput sequencing. Protein expression was analyzed by means of Western blotting, and glycosylation was profiled by using mass spectrometry.Results
Mutational analysis of candidate genes in an 11.9-Mb linkage region on chromosome 6 shared by 2 multiplex families identified 2 homozygous mutations in PGM3 that segregated with disease status and followed recessive inheritance. The mutations predict amino acid changes in PGM3 (p.Glu340del and p.Leu83Ser). A third homozygous mutation (p.Asp502Tyr) and the p.Leu83Ser variant were identified in 2 other affected families, respectively. These hypomorphic mutations have an effect on the biosynthetic reactions involving uridine diphosphate N-acetylglucosamine. Glycomic analysis revealed an aberrant glycosylation pattern in leukocytes demonstrated by a reduced level of tri-antennary and tetra-antennary N-glycans. T-cell proliferation and differentiation were impaired in patients. Most patients had developmental delay, and many had psychomotor retardation.Conclusion
Impairment of PGM3 function leads to a novel primary (inborn) error of development and immunity because biallelic hypomorphic mutations are associated with impaired glycosylation and a hyper-IgE-like phenotype.